Advertisement

Biologics

  • Sahil Sekhon
  • Caleb Jeon
  • Wilson Liao
Chapter
Part of the Updates in Clinical Dermatology book series (UCD)

Abstract

Biologic medications used in the treatment of psoriasis are antibodies or proteins that target specific components of the immune system. Biologics have revolutionized the treatment of psoriasis due to their overall high efficacy and excellent safety. Currently, seven biologic agents are approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis vulgaris: adalimumab, brodalumab, etanercept, infliximab, ixekizumab, secukinumab, and ustekinumab. To date, these various biologics target the action of three inflammatory cytokines including TNF-alpha, IL-12/23 p40, and IL-17. Newer biologics in development are aimed at additional molecular targets including IL-23 p19, TBK1, IKK1ε, RORγt, and the combination of IL-17/TNF-α . This chapter focuses on biologics currently approved by the US FDA for treatment of psoriasis vulgaris.

Keywords

Biologics Psoriasis Adalimumab Brodalumab Etanercept Infliximab Ixekizumab Secukinumab Ustekinumab IL-17 Interleukin-17 IL-12 Interleukin-12 IL-23 Interleukin 23 TNF-α Tumor necrosis factor-alpha Antibodies Efficacy Safety 

References

  1. 1.
    Menter A, Tyring S, Gordon K, Kimball A, Leonardi C, Langley R, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Saurat J, Stingl G, Dubertret L, Papp K, Langley R, Ortonne J, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2007;158(3):558–66.CrossRefPubMedGoogle Scholar
  3. 3.
    Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso E. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Leonardi C, Powers J, Matheson R, Goffe B, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Papp K, Tyring S, Lahfa M, Prinz J, Griffiths C, Nakanishi A, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Reich K, Nestle F, Papp K, Ortonne J, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Menter A, Feldman S, Weinstein G, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–31.e15.CrossRefGoogle Scholar
  8. 8.
    Gottlieb A, Evans R, Li S, Dooley L, Guzzo C, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Leonardi C, Kimball A, Papp K, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Papp K, Langley R, Lebwohl M, Krueger G, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Griffiths C, Strober B, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–28.CrossRefPubMedGoogle Scholar
  12. 12.
    Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Papp K, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86.CrossRefPubMedGoogle Scholar
  14. 14.
    Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.CrossRefPubMedGoogle Scholar
  15. 15.
    Blauvelt A, Prinz J, Gottlieb A, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2014;172(2):484–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Paul C, Lacour J, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2014;29(6):1082–90.CrossRefPubMedGoogle Scholar
  17. 17.
    Blauvelt A, Reich K, Tsai T, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60–69.e9.CrossRefPubMedGoogle Scholar
  18. 18.
    Gordon K, Blauvelt A, Papp K, Langley R, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56.CrossRefPubMedGoogle Scholar
  19. 19.
    Griffiths C, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Enbrel [package insert]. Thousand Oaks: Immunex Corporation; 2016.Google Scholar
  21. 21.
    Gottlieb AB, Lowe NJ, Matheson RT et al. Efficacy of etanercept in patients with psoriasis. Presented at the American Academy of Dermatology, New Orleans, LA, USA, 22–27 February 2002.Google Scholar
  22. 22.
    Gordon K, Gottlieb A, Leonardi C, Elewski B, Wang A, Jahreis A, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatol Treat. 2006;17(1):9–17.CrossRefGoogle Scholar
  23. 23.
    Bagel J, Tyring S, Rice K, Collier D, Kricorian G, Chung J, et al. Open-label study of etanercept treatment in patients with moderate to severe plaque psoriasis who lost a satisfactory response to adalimumab. Br J Dermatol. 2017;177:411.CrossRefPubMedGoogle Scholar
  24. 24.
    Hsu L, Snodgrass B, Armstrong A. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Paller A, Siegfried E, Langley R, Gottlieb A, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Langley R, Paller A, Hebert A, Creamer K, Weng H, Jahreis A, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Mohan N, Edwards E, Cupps T, Oliverio P, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor ? Therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Sicotte N, Voskuhl R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Mercieca C, Vella N, Borg A. Demyelination during anti-TNFα therapy for ankylosing spondylitis. Mod Rheumatol. 2011;22(2):303–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Sorenson E, Koo J. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: providing clarity to an opaque topic. J Dermatol Treat. 2015;26(6):493–501.CrossRefGoogle Scholar
  31. 31.
    Pariser D, Leonardi C, Gordon K, Gottlieb A, Tyring S, Papp K, et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012;67(2):245–56.CrossRefPubMedGoogle Scholar
  32. 32.
    Papp K, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66(2):e33-e45.CrossRefGoogle Scholar
  33. 33.
    Kimball A, Rothman K, Kricorian G, Pariser D, Yamauchi P, Menter A, et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015;72(1):115–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Humira [package insert]. North Chicago: AbbVie Inc.; 2016.Google Scholar
  35. 35.
    Prussick R, Unnebrink K, Vandecantos WC. Efficacy of Adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis. J Drugs Dermatol. 2015;14(8):864–8.PubMedGoogle Scholar
  36. 36.
    Papp K, Armstrong A, Reich K, Karunaratne M, Valdecantos W. Adalimumab efficacy in patients with psoriasis who received or did not respond to prior systemic therapy: a pooled post hoc analysis of results from three double-blind, placebo-controlled clinical trials. Am J Clin Dermatol. 2015;17(1):79–86.CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Ortonne J, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol. 2011;25(9):1012–20.CrossRefPubMedGoogle Scholar
  38. 38.
    Strober B, Poulin Y, Kerdel F, Langley R, Gu Y, Gupta S, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64(4):671–81.CrossRefPubMedGoogle Scholar
  39. 39.
    Menting S, van Lümig P, de Vries A, van den Reek J, van der Kleij D, de Jong E, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis. JAMA Dermatol. 2014;150(2):130.CrossRefPubMedGoogle Scholar
  40. 40.
    Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis. Am J Clin Dermatol. 2011;12(5):321–37.CrossRefPubMedGoogle Scholar
  41. 41.
    Burmester G, Mease P, Dijkmans B, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68(12):1863–9.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Burmester G, Panaccione R, Gordon K, McIlraith M, Lacerda A. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2012;72(4):517–24.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Reich K, Wozel G, Zheng H, van Hoogstraten H, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Levin E, Debbaneh M, Koo J, Liao W. Biologic therapy in erythrodermic and pustular psoriasis. J Drugs Dermatol. 2014;13(3):342–54.PubMedGoogle Scholar
  45. 45.
    Shear N, Hartmann M, Toledo-Bahena M, Katsambas A, Connors L, Chang Q, et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol. 2014;171(3):631–41.CrossRefPubMedGoogle Scholar
  46. 46.
    Harding F, Stickler M, Razo J, DuBridge R. The immunogenicity of humanized and fully human antibodies. MAbs. 2010;2(3):256–65.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, et al. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76(2):334–41.CrossRefPubMedGoogle Scholar
  48. 48.
    Zhu T, Nakamura M, Abrouk M, Farahnik B, Koo J, Bhutani T. Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: a review. J Dermatol Treat. 2016;27(5):406–13.CrossRefGoogle Scholar
  49. 49.
    Tesmer L, Lundy S, Sarkar S, Fox D. Th17 cells in human disease. Immunol Rev. 2008;223(1):87–113.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Murphy K, Reiner S. Decision making in the immune system: the lineage decisions of helper T cells. Nat Rev Immunol. 2002;2(12):933–44.CrossRefPubMedGoogle Scholar
  51. 51.
    Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19(3):281–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Oppmann B, Lesley R, Blom B, Timans J, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–25.CrossRefPubMedGoogle Scholar
  53. 53.
    Harrington L, Hatton R, Mangan P, Turner H, Murphy T, Murphy K, et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32.CrossRefPubMedGoogle Scholar
  54. 54.
    Vignali D, Kuchroo V. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13(8):722–8.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Krueger G, Langley R, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–92.CrossRefPubMedGoogle Scholar
  56. 56.
    Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63(4):571–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Griffiths CEM, Strober B, Fidelus-Gort R, Menter A. A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. P3318. 2009 AAD meeting; San Francisco.Google Scholar
  58. 58.
    Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398–407.CrossRefPubMedGoogle Scholar
  59. 59.
    Kimball A, Papp K, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2012;27(12):1535–45.CrossRefPubMedGoogle Scholar
  60. 60.
    Langley R, Lebwohl M, Krueger G, Szapary P, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–83.CrossRefPubMedGoogle Scholar
  61. 61.
    Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatol Treat. 2010;22(6):337–47.CrossRefGoogle Scholar
  62. 62.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162(1):137–46.CrossRefPubMedGoogle Scholar
  63. 63.
    Kimball A, Gordon K, Fakharzadeh S, Yeilding N, Szapary P, Schenkel B, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–72.CrossRefPubMedGoogle Scholar
  64. 64.
    Brodmerkel C, Wadman E, Langley R, Papp K, Bourcier M, Poulin Y, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013;12(10):1122–9.PubMedGoogle Scholar
  65. 65.
    Lebwohl M, Leonardi C, Griffiths C, Prinz J, Szapary P, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66(5):731–41.CrossRefPubMedGoogle Scholar
  66. 66.
    Tsai T, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145–52.CrossRefPubMedGoogle Scholar
  67. 67.
    Krueger J, Fretzin S, Suárez-Fariñas M, Haslett P, Phipps K, Cameron G, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–154.e9.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Canavan T, Elmets C, Cantrell W, Evans J, Elewski B. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2015;17(1):33–47.CrossRefGoogle Scholar
  69. 69.
    Taltz [package insert]. Indianapolis: Eli Lilly and Company; 2016.Google Scholar
  70. 70.
    Wang C, Suárez-Fariñas M, Nograles K, Mimoso C, Shrom D, Dow E, et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Investig Dermatol. 2014;134(12):2990–3.CrossRefPubMedGoogle Scholar
  71. 71.
    Syed Y. Ixekizumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2017;18(1):147–58.CrossRefPubMedGoogle Scholar
  72. 72.
    Blauvelt A, Cameron G, Gordon K, et al. Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis [abstract no. 3232]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB258.Google Scholar
  73. 73.
    Kimball A, Schenfeld J, Accortt N, Anthony M, Rothman K, Pariser D. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol. 2014;170(2):366–73.CrossRefPubMedGoogle Scholar
  74. 74.
    Reich K, Leonardi C, Langley R, Warren R, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441–448.e2.CrossRefPubMedGoogle Scholar
  75. 75.
    Strober B, Leonardi C, Papp K, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–440.e17.CrossRefPubMedGoogle Scholar
  76. 76.
    Cosentyx [package insert]. East Hanover: Novartis Pharmaceuticals Corporation; 2015.Google Scholar
  77. 77.
    Thaçi D, Blauvelt A, Reich K, Tsai T, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.CrossRefPubMedGoogle Scholar
  78. 78.
    Lacour J, Paul C, Jazayeri S, Papanastasiou P, Xu C, Nyirady J, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31:847.CrossRefPubMedGoogle Scholar
  79. 79.
    Mrowietz U, Leonardi C, Girolomoni G, Toth D, Morita A, Balki S, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27–36.e1.CrossRefPubMedGoogle Scholar
  80. 80.
    Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80.CrossRefPubMedGoogle Scholar
  81. 81.
    Paul C, Reich K, Gottlieb A, Mrowietz U, Philipp S, Nakayama J, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670–5.CrossRefPubMedGoogle Scholar
  82. 82.
    Sigurgeirsson B, Kircik L, Nemoto O, Mikazans I, Haemmerle S, Thurston H, et al. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. J Eur Acad Dermatol Venereol. 2013;28(8):1127–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Siliq [package insert]. Bridgewater: Valeant Pharmaceuticals; 2017.Google Scholar
  84. 84.
    Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo controlled study through week 12. In: Presented at the 73rd annual meeting of the American Academy of Dermatology; 2015 March 20–24; San Francisco, CA.Google Scholar
  85. 85.
    Farahnik B, Beroukhim K, Abrouk M, Nakamura M, Zhu T, Singh R, et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2016;6(2):111–24.CrossRefGoogle Scholar
  86. 86.
    Puel A, Cypowyj S, Bustamante J, Wright J, Liu L, Lim H, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Gaffen S, Hernández-Santos N, Peterson A. IL-17 signaling in host defense against Candida albicans. Immunol Res. 2011;50(2–3):181–7.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Hueber W, Sands B, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins P, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Mozaffari S, Nikfar S, Abdollahi M. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs. 2015;24(7):949–56.CrossRefPubMedGoogle Scholar
  90. 90.
    Huang W, Cordoro K, Taylor S, Feldman S. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol. 2008;58(6):970–7.CrossRefPubMedGoogle Scholar
  91. 91.
    Testing Recommendations for Hepatitis C Virus Infection | HCV | Division of Viral Hepatitis | CDC [Internet]. Cdc.gov. 2017 [cited 7 April 2017]. https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm
  92. 92.
    Menter A, Gottlieb A, Feldman S, Van Voorhees A, Leonardi C, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2008;58(5):826–50.CrossRefPubMedGoogle Scholar
  93. 93.
    Campa M, Menter A. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies. Expert Opin Investig Drugs. 2016;25(11):1337–44.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Dermatology, UCSF Psoriasis CenterUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations